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This large series describing the clinical and laboratory features of the rare leukemia NT-AML showed that most European patients displayed involvement of at least two myeloid lineages reflected by morphology and immunophenotype. The undifferentiated morphology of NT-blasts observed in the 40% of cases with M0 AML stresses the fact that it may be difficult to establish a proper diagnosis of NT-AML without immunophenotypic examination. Cytogenetic findings displayed at least one abnormality of chromosomes 5, 7, 1, 2, 3, and/or 17. The outcome of these patients was poor after standard chemotherapy 7 but our data suggest that patients with de novo NT-AML might benefit from therapy with intermediate or high doses of cytosine-arabinoside combined with anthracyclines for CR induction and/or consolidation, followed by autologous stem cell transplantation in first CR. Family studies demonstrate that there is an inherited component in a significant proportion of CLL patients. The average age of onset in familial CLL is approximately 10-20 years earlier than in sporadic CLL, suggesting that familial anticipation occurs although this may be due to ascertainment bias. 1, 2 We have previously reported the development of a sensitive flow cytometric assay which can detect as little as a single CLL cell in 10 5 leucocytes without prior knowledge of any immunophe-notype or genotype. 3 This assay is therefore applicable to identifying extremely low levels of clonal CLL cells in apparently normal individuals. It is possible to detect a monoclonal B-cell lymphocytosis with CLL-phenotype (MBL-CLL) in 3.5% of healthy individuals over 40 years old (32/910). 4 In 59 healthy first-degree relatives of patients from 21 CLL families, MBL-CLL was detected in 8/59 relatives (13.5%), representing a highly significant increase in prevalence (age-adjusted logistic regression analysis, P ¼ 0.00002). 5 These data have now been confirmed in independent studies. 6, 7 Two of the eight individuals were under 40 years old, and to directly compare these relatives with appropriate controls we have screened a further 365 normal individuals aged 16-40 years. MBL-CLL was detectable in only 0.3% (1/365) of the otherwise normal young adults. The age distribution of MBL-CLL in normal individuals therefore mimics that of clinical CLL; in contrast the proportion of affected individuals in familial CLL is high at all ages. The overall relative risk for detection of MBL-CLL in families is fourfold in comparison to the general population but for young adults the relative risk rises to 17-fold ( Table 1 ). The detection of MBL-CLL is independent of ascertainment bias and provides strong confirmatory evidence of inherited genetic susceptibility to CLL in some families. The fact that familial CLL shares a similar range and frequency of the major prognostic factors 8 indicates that there is a pre-disposition to all types of CLL. The data suggests that, at least in a proportion of families, there is an inherited abnormality that increases susceptibility to development of CLL at a much earlier age than the general population, thus increasing the life-long risk of developing a clinically apparent CLL clone within the family as a whole. Adoptive T-cell immunotherapy is an attractive modality for the treatment of human hematologic malignancies. Genetic engineering of T lymphocytes with chimeric T-cell receptors (cTCR) has been shown to be a potent strategy for targeted immunotherapy. 1 A variety of cTCR have been constructed, some of which consist of a single-chain antibody variable fragment (scFv) with tumor antigen specificity linked to the constant region of the CD3z-chain of the TCR. 2 cTCR expressing T lymphocytes can bypass MHC-restricted target recognition and have shown significant tumor responses in models. However, clinical efficacy in humans is, as yet limited. The reasons for this are not well understood, but incomplete activation via the signaling domain of the CD3z-chain is thought to be one major limitation for successful clinical application.
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